Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE

Title

Adherence to low molecular weight heparin treatment by patients with cancer who develop VTE

Share this page

Patients with cancer who are diagnosed with venous thromboembolism (VTE) are managed with low molecular weight heparin (enoxaparin), an established treatment. Those with incidental VTE are generally stable and can be treated as outpatients, and their knowledge and ability to self-administer injections contributes to treatment adherence. However, the limited, or absence of, signs and symptoms associated with incidental VTE can affect adherence. This article reports the results of an audit that examined patients’ understanding of VTE, and the information they receive from healthcare professionals to support self-management. The audit found there is a difference in adherence between patients with incidental VTE and those who have symptomatic events. Results demonstrate the need for written information and a clear management pathway.

Want the full article and instant web access?

Explore more and be inspired with a subscription for this journal

  • 1000's of clinical and research articles
  • Interactive CPD articles
  • RCNi portfolio for revalidation

Subscribe now

Already a subscriber? Sign InInstitutional subscriber? Sign in